A wide-moat Blue Cross franchise at a trough multiple—if CMS clears and Medicaid rates catch up, Carelon can re-rate Elevance from insurer to services platform.
Overview
Elevance Health (ELV) is a leading U.S. managed-care company serving ~45M members through a two-part model: the legacy Health Benefits insurance segment and the faster-growing Carelon services platform. The company’s moat is anchored by exclusive Blue Cross Blue Shield licenses in 14 states, delivering local brand strength and strong provider contracting leverage. ELV is in a strategic pivot described as a 2026 “trough year,” intentionally trading near-term government membership growth for margin reset and positioning for 12%+ adjusted EPS growth starting in 2027. Near-term complexity is heightened by a CMS notice on historical Medicare Advantage risk-adjustment data, prompting a $935M Q1’26 accrual and raising the risk of sanctions/enrollment constraints. Despite these headwinds, Q1’26 results showed resilience: revenue of $49.5B beat expectations and adjusted EPS of $12.58 materially exceeded consensus, aided by strong investment income and disciplined administrative spending. The core thesis is that the market is over-discounting temporary regulatory/margin pressure while underappreciating Carelon’s ability to evolve from an internal cost-management arm into an external-facing healthcare services growth engine.